Raymond James Financial
BIAF icon

Raymond James Financial’s bioAffinity Technologies BIAF Stock Holding History

Raymond James Financial’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17
Closed -$144 – 5156
2025
Q2 		$144 Buy
+17
New +$194 ﹤0.01% 6813

Other funds holding BIAF

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return

Raymond James Financial's BIAF Position: Q3 2025 in Review

Raymond James Financial sold out of bioAffinity Technologies (BIAF) in Q3 2025, closing a stake of 17 shares — an estimated $144 sold.

Raymond James Financial first reported a position in BIAF in Q2 2025 and held it in 1 quarter. The position peaked at $144 in Q2 2025. 12 funds tracked by Wall St. Rank hold BIAF as of Q3 2025.

  • Raymond James Financial reported no remaining bioAffinity Technologies position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 17 bioAffinity Technologies shares in Q3 2025, an estimated $144.
  • Raymond James Financial first reported a position in bioAffinity Technologies in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's bioAffinity Technologies position peaked at $144 in Q2 2025.
  • 12 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.